Drug Topics
JULY 1, 2024
Drug Topics sat down with Sandra Canally, RN, founder and CEO of The Compliance Team, and Kara Benson, PharmD, long-term care director of Lewis Drug Inc, to discuss the future of LTC pharmacy.
STAT
JULY 1, 2024
There has been much handwringing about how difficult it is for Americans with mental health issues to see a psychiatrist. Failures in the health insurance market are often blamed for the problem. As a new class of psychiatry residents begins work in hospitals across the country this week, I see an additional cause: the lack of commitment to honor the subsidies that made it possible for psychiatrists to enter the profession.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
JULY 1, 2024
Research presented at the American Diabetes Association 84th Scientific Sessions suggests a population approach to CGM use could be beneficial.
Fierce Healthcare
JULY 1, 2024
As its stack of unpaid vendor obligations climbed, now-bankrupt Steward Health Care paid private investigators millions of dollars to follow and uncover compromising information on individuals | An investigative report details a "spare no expenses mission" in which executives authorized intelligence firms to allegedly follow, data mine and disseminate damaging information about individuals viewed as opponents.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
JULY 1, 2024
Bird flu snapshot: This is the latest installment in a series of regular updates on H5N1 avian flu that STAT is publishing on Monday mornings. To read future updates you can also subscribe to STAT’s Morning Rounds newsletter. When pathologist Thijs Kuiken looks at what’s happening in the U.S. response to the H5N1 bird flu outbreak in dairy cows, he’s reminded of a difficult period in the Netherlands, where he lives, back in the late aughts.
Fierce Healthcare
JULY 1, 2024
Digital primary care startup K Health raised $50 million in an equity funding round to build out its AI-powered medical services and fuel its growth, the company announced Monday. | Digital primary care startup K Health raised $50 million in an equity funding round to build out its AI-powered medical services and fuel its growth, the company announced Monday.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Healthcare
JULY 1, 2024
OptumRx will pay $20 million to resolve claims the company violated the Controlled Substances Act by improperly filling certain opioid prescriptions, the Department of Justice recently announced.
Drug Topics
JULY 1, 2024
Jeremy Cundiff, PharmD, co-owner of Professional Pharmacy Group, joined Drug Topics to discuss Return Solutions and the company’s Rx Returns process.
STAT
JULY 1, 2024
A novel surgical technique could dramatically improve walking for people with below-the-knee amputations and help them better control their prosthetics. A study published Monday in Nature Medicine showed that trial participants who received the procedure could walk faster, were more stable on uneven terrain, and had an increased spatial awareness, or proprioception, in their residual limb.
Pharmacy Times
JULY 1, 2024
Ustekinumab-ttwe (Pyzchiva; Sandoz) is approved for all indications of Stelara.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
JULY 1, 2024
AstraZeneca may have exited the COVID-19 vaccine market, but it is still hoping to protect vulnerable patients with its antibody sipavibart for pre-exposure prophylaxis (PrEP).The drugmaker said this morning that an application for sipavibart (AZD3152) has been accepted for review by the EMA as PrEP for immunocompromised patients who often do not respond adequately to vaccination alone and remain at high risk of serious outcomes from COVID-19.
STAT
JULY 1, 2024
The microbiome has immense power to shape health outcomes. The bacteria that take up residence in the human body, including the gut, have been shown to impact health and disease, including neurodegenerative disorders. Medical research is invested in finding ways to reconstruct healthy microbiomes to help cure some of those ills. But like many fields in science , microbiome research is suffering from a reproducibility crisis.
The Checkup by Singlecare
JULY 1, 2024
Quercetin is a flavonoid, a compound that gives plants—including fruits, vegetables, herbs, and flowers—their color. It’s found in many common foods and drinks, such as citrus fruit, apples, onions, buckwheat, cherries, berries, broccoli, red wine, green tea, parsley, sage, dill, and coriander. It’s also available as a supplement. If you’ve noticed it in grocery and drug store aisles recently, it may be because this dietary antioxidant is becoming more popular.
STAT
JULY 1, 2024
The Federal Trade Commission is formally investigating Teva Pharmaceuticals after the company refused to remove approximately two dozen patents for asthma and COPD inhalers from a key federal registry. The agency sent a civil investigative demand requiring Teva to provide information related to the patents listed in the so-called Orange Book, which is maintained by the Food and Drug Administration.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
JULY 1, 2024
Informed patient consent is crucial for the success of clinical trials. Learn about the importance of consent in clinical trials and how it impacts the outcomes.
Pharmacy Times
JULY 1, 2024
Perinatal depression increases the risk of cardiovascular disease in women.
pharmaphorum
JULY 1, 2024
Eli Lilly has lined up another deal in the radiopharmaceutical sector, paying $140 million to partner drugs developed by Radionetics Oncology and taking an option on buying the company outright for $1 billion.Radionetics is working on small-molecule drugs that target G protein-coupled receptors (GPCRs), a fertile source of drug targets for the pharma industry and the target of around a third of all marketed drugs but according to the company is a “largely unexplored” class for radiopharma.
Pharmacy Times
JULY 1, 2024
The monotherapy is compared with the combination regimen of elotuzumab plus pomalidomide and dexamethasone in adult patients with relapsed or refractory multiple myeloma.
pharmaphorum
JULY 1, 2024
France's HAS agrees to fund treatment with Carthera's ultrasound device for French subjects enrolled in a glioblastoma trial.
Pharmacy Times
JULY 1, 2024
As the data management landscape continues to shift and change with AI and technological advancements all around us, it is essential to maintain good data practices and ensure data integrity in pharmaceutical research and development.
STAT
JULY 1, 2024
My dad, Randy, a 72-year-old retired sales manager, started to gain weight after grad school, and it didn’t let up until he was middle-aged. He’s now living with high blood pressure and high cholesterol. His cardiologist has told him, “You know, if you lost 15 pounds, you could get off your blood pressure medicine.
Fierce Pharma
JULY 1, 2024
In yet another legal development surrounding counterfeit HIV drugs, a Florida court has handed down an indictment for the owners of a wholesale distributor that allegedly bought and redistribu | The wholesaler Safe Chain allegedly purchased $90 million of misbranded, diverted and adulterated HIV meds, according to U.S. authorities. The indictment of the company's three owners follows separate lawsuits from Gilead and Johnson & Johnson.
pharmaphorum
JULY 1, 2024
NeuroSense Tx reports 12-month data with its amyotrophic lateral sclerosis therapy PrimeC, including a 43% improvement in survival
Fierce Pharma
JULY 1, 2024
GSK scratched another Zantac lawsuit off the list with a confidential settlement in Illinois as it continues to work through the mountain of personal injury litigation related to the heartburn pill | Following a win and a separate dismissal in Illinois, GSK agreed to a confidential settlement to resolve prostate cancer claims put forward by plaintiff Martin Gross.
European Pharmaceutical Review
JULY 1, 2024
At its recent June meeting, the EMA’s human medicines committee (CHMP) recommended 10 medicines for approval. Recommendations for regulatory approval The committee saw a need to give a marketing authorisation to Balversa (erdafitinib) as a treatment for adults with unresectable or metastatic urothelial carcinoma. In its meeting, the CHMP gave a positive opinion for the first nasally administered emergency treatment for allergic reactions.
Fierce Pharma
JULY 1, 2024
Less than three weeks after a group of cancer victims filed a motion against Johnson & Johnson attempting to block the company’s latest bankruptcy plan—which comes with a $6.5 billion class-act | Less than three weeks after a group of cancer victims filed a motion attempting to block Johnson & Johnson's latest talc litigation bankruptcy plan—which comes with a $6.5 billion class-action settlement offer—a New Jersey federal court has quashed the effort.
Pharmacy Times
JULY 1, 2024
Additionally, birth weight was higher in babies born to mothers who were prescribed glucagon-like peptide-1 (GLP-1) medications either 90 days prior to pregnancy or during the first trimester.
Fierce Pharma
JULY 1, 2024
Welcome to Fierce Pharma's regulatory tracker for the second half of 2024. | In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.
Pharmacy Times
JULY 1, 2024
RCT1100 is designed to deliver DNAI1 mRNA directly to affected airways through an inhaled nebulizer and fills an urgent unmet need in the treatment of those with primary ciliary dyskinesia.
Fierce Pharma
JULY 1, 2024
Fierce Pharma explored the status of the industry's noncompete clauses with experts to learn whether an intercompany transition at the highest levels can proceed without a hitch.
STAT
JULY 1, 2024
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because the familiar routine of online meetings, calls, and deadlines has predictably returned. But you know, the world — such as it is — continues to spin. So what can you do but try to give it a nudge in a better direction.
Pharmaceutical Technology
JULY 1, 2024
Atirmociclib is a small molecule commercialized by Pfizer, with a leading Phase III program in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).
Pharmacy Times
JULY 1, 2024
Experts give important background information on respiratory syncytial virus (RSV), as well as the key clinical considerations that are associated with RSV vaccine use.
Fierce Healthcare
JULY 1, 2024
Leading telenutrition platform Foodsmart banked a $200 million investment from The Rise Fund, which backs entrepreneurs working to achieve the United Nations’ Sustainable Development Goals.
Expert insights. Personalized for you.
211 
Let's personalize your content